m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00330)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MAPK14
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | HeLa cell line | Homo sapiens |
Treatment: METTL3 knockdown HeLa cells
Control: HeLa cells
|
GSE70061 | |
Regulation |
|
logFC: -3.87E+00 p-value: 1.84E-03 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between MAPK14 and the regulator | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Regulation | logFC: 1.30E+00 | GSE60213 |
In total 2 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | High METTL3 expression was positively correlated with more severe clinical features of OSCC tumors. Furthermore, METTL3-KD and cycloleucine, a methylation inhibitor, decreased m6A levels and down-regulated Mitogen-activated protein kinase 14 (p38/MAPK14) expression in OSCC cells. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Oral squamous cell carcinoma | ICD-11: 2B6E.0 | ||
In-vitro Model | SCC-25 | Tongue squamous cell carcinoma | Homo sapiens | CVCL_1682 |
SCC-15 | Tongue squamous cell carcinoma | Homo sapiens | CVCL_1681 | |
In-vivo Model | Male BALB/c-nu/nu mice, 9-10 weeks of age, were acclimatized for a week prior to the experiments. Nude mice (6 each group) were subcutaneously inoculated with 4 × 106 SCC-25 or SCC-15 cells through an injection into the center of the back, which consistently caused tumor formation within 1 week of inoculation. To monitor the initial tumor appearance, animals were observed every day. After tumor appeared, measurements were made every week with a caliper. After 28 days, mice were sacrificed and tumors were dissected out to be weighed. | |||
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | METTL3 played a tumor-suppressive role in Colorectal cancer cell proliferation, migration and invasion through Mitogen-activated protein kinase 14 (p38/MAPK14)/ERK pathways, which indicated that METTL3 was a novel marker for CRC carcinogenesis, progression and survival. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
KM12 | Colon carcinoma | Homo sapiens | CVCL_1331 | |
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) [READER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | N6-methyladenosine (m6A) methylation modification is implicated in the pathogenesis of lung ischemia-reperfusion injury. YTHDF3 or IGF2BP2 knockdown inhibited hypoxia/reoxygenation-activated Mitogen-activated protein kinase 14 (p38/MAPK14), ERK1/2, AKT, and NF-Kappa-B pathways in BEAS-2B cells, and inhibited p-p65, IL-1-beta and TNF-alpha secretion. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Gangrene or necrosis of lung | ICD-11: CA43 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Cell Process | Biological regulation | |||
Cell apoptosis | ||||
In-vitro Model | BEAS-2B | Normal | Homo sapiens | CVCL_0168 |
In-vivo Model | After being anesthetized with urethane (i.p.), SD rats were endotracheally intubated and ventilated using an animal ventilator under the conditions: respiratory rate of 70 breaths/min, tidal volume of 20 ml/kg, and inspiratory/expiratory ratio of 1:1. | |||
YTH domain-containing family protein 3 (YTHDF3) [READER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | N6-methyladenosine (m6A) methylation modification is implicated in the pathogenesis of lung ischemia-reperfusion injury. YTHDF3 or IGF2BP2 knockdown inhibited hypoxia/reoxygenation-activated Mitogen-activated protein kinase 14 (p38/MAPK14), ERK1/2, AKT, and NF-Kappa-B pathways in BEAS-2B cells, and inhibited p-p65, IL-1-beta and TNF-alpha secretion. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Gangrene or necrosis of lung | ICD-11: CA43 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Cell Process | Biological regulation | |||
Cell apoptosis | ||||
In-vitro Model | BEAS-2B | Normal | Homo sapiens | CVCL_0168 |
In-vivo Model | After being anesthetized with urethane (i.p.), SD rats were endotracheally intubated and ventilated using an animal ventilator under the conditions: respiratory rate of 70 breaths/min, tidal volume of 20 ml/kg, and inspiratory/expiratory ratio of 1:1. | |||
Head and neck squamous carcinoma [ICD-11: 2B6E]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | High METTL3 expression was positively correlated with more severe clinical features of OSCC tumors. Furthermore, METTL3-KD and cycloleucine, a methylation inhibitor, decreased m6A levels and down-regulated Mitogen-activated protein kinase 14 (p38/MAPK14) expression in OSCC cells. | |||
Responsed Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
In-vitro Model | SCC-25 | Tongue squamous cell carcinoma | Homo sapiens | CVCL_1682 |
SCC-15 | Tongue squamous cell carcinoma | Homo sapiens | CVCL_1681 | |
In-vivo Model | Male BALB/c-nu/nu mice, 9-10 weeks of age, were acclimatized for a week prior to the experiments. Nude mice (6 each group) were subcutaneously inoculated with 4 × 106 SCC-25 or SCC-15 cells through an injection into the center of the back, which consistently caused tumor formation within 1 week of inoculation. To monitor the initial tumor appearance, animals were observed every day. After tumor appeared, measurements were made every week with a caliper. After 28 days, mice were sacrificed and tumors were dissected out to be weighed. | |||
Colorectal cancer [ICD-11: 2B91]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | METTL3 played a tumor-suppressive role in Colorectal cancer cell proliferation, migration and invasion through Mitogen-activated protein kinase 14 (p38/MAPK14)/ERK pathways, which indicated that METTL3 was a novel marker for CRC carcinogenesis, progression and survival. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | DLD-1 | Colon adenocarcinoma | Homo sapiens | CVCL_0248 |
HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 | |
HCT 8 | Colon adenocarcinoma | Homo sapiens | CVCL_2478 | |
KM12 | Colon carcinoma | Homo sapiens | CVCL_1331 | |
Gangrene or necrosis of lung [ICD-11: CA43]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | N6-methyladenosine (m6A) methylation modification is implicated in the pathogenesis of lung ischemia-reperfusion injury. YTHDF3 or IGF2BP2 knockdown inhibited hypoxia/reoxygenation-activated Mitogen-activated protein kinase 14 (p38/MAPK14), ERK1/2, AKT, and NF-Kappa-B pathways in BEAS-2B cells, and inhibited p-p65, IL-1-beta and TNF-alpha secretion. | |||
Responsed Disease | Gangrene or necrosis of lung [ICD-11: CA43] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Cell Process | Biological regulation | |||
Cell apoptosis | ||||
In-vitro Model | BEAS-2B | Normal | Homo sapiens | CVCL_0168 |
In-vivo Model | After being anesthetized with urethane (i.p.), SD rats were endotracheally intubated and ventilated using an animal ventilator under the conditions: respiratory rate of 70 breaths/min, tidal volume of 20 ml/kg, and inspiratory/expiratory ratio of 1:1. | |||
Experiment 2 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | N6-methyladenosine (m6A) methylation modification is implicated in the pathogenesis of lung ischemia-reperfusion injury. YTHDF3 or IGF2BP2 knockdown inhibited hypoxia/reoxygenation-activated Mitogen-activated protein kinase 14 (p38/MAPK14), ERK1/2, AKT, and NF-Kappa-B pathways in BEAS-2B cells, and inhibited p-p65, IL-1-beta and TNF-alpha secretion. | |||
Responsed Disease | Gangrene or necrosis of lung [ICD-11: CA43] | |||
Target Regulator | YTH domain-containing family protein 3 (YTHDF3) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Cell Process | Biological regulation | |||
Cell apoptosis | ||||
In-vitro Model | BEAS-2B | Normal | Homo sapiens | CVCL_0168 |
In-vivo Model | After being anesthetized with urethane (i.p.), SD rats were endotracheally intubated and ventilated using an animal ventilator under the conditions: respiratory rate of 70 breaths/min, tidal volume of 20 ml/kg, and inspiratory/expiratory ratio of 1:1. | |||
References